Melanotan II: what it is, the research, and its legal status in 2026
✓ Every claim cited to a primary source
· Last verified: July 4, 2026
Melanotan II
Synthetic α-MSH analog · melanocortin-receptor agonist
Illustration by Peppies.
A short explainer: what Melanotan II is, what the research shows, and where it stands with regulators.
Also called
MT-II; MT-2
Type
Synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH)1
Origin
Developed at the University of Arizona in the 1990s1
FDA approval
None - FDA has warned consumers against unapproved tanning injections3
Research stage
Case reports and reviews document serious adverse events; no approved use12
Safety
Associated with rhabdomyolysis, kidney injury, cardiovascular effects12
U.S. status (Jul 2026)
Later review expected
What Melanotan II is
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), originally developed in the 1990s at the University of Arizona.1 It binds broadly to the body's melanocortin receptors (MC1R-MC5R), which is why it affects pigmentation but also has effects on the cardiovascular, gastrointestinal, and other systems that cannot be cleanly separated from the tanning effect.12
Melanotan II has never been approved by the FDA for any use.3
In plain English: Melanotan II is a lab-made peptide that can darken skin (a tan) without much sun.
What the research shows - and the safety concerns
Unlike some peptides here, Melanotan II carries a substantial safety signal. Published case reports and reviews document serious adverse events associated with its use, including rhabdomyolysis (muscle breakdown), kidney injury and renal infarction, cardiovascular effects, nausea, and priapism.12 Concerns about changes to moles and melanoma risk
have also been raised.2
Safety note. The FDA has repeatedly warned consumers against unapproved injectable "tanning" products such as Melanotan II. This peptide is associated with documented, sometimes serious harms, and no controlled trial has established a safe dose.123
A candid word on Melanotan II
We'll be straight with you, because this one is different. Melanotan II's draw is obvious - the promise of a deep tan with little sun, plus reported effects on libido and appetite - which is exactly why it spread through the grey market.1 But this is the peptide in the group where the honest story tilts toward caution, not enthusiasm: it is tied to real, documented harms, and no controlled
trial has established a safe dose.12 Building trust means telling you that plainly.
How to read peptide research. Animal-study and cell-study findings describe what happened in a controlled experiment. They are a starting point for investigation, not evidence that a compound works - or is safe - in humans. Peppies does not claim any peptide treats, cures, or prevents any condition.
In plain English: People use it for tanning, but it's linked to real harms - like severe muscle and kidney problems - and no safe dose has been proven. This is the one to be careful with.
Is Melanotan II legal in 2026?
Here is the direct answer as of July 2026:
It is not an FDA-approved drug. There is no approved Melanotan II product for any medical use.
The FDA has issued public warnings against it. Melanotan II has been the subject of FDA consumer warnings about unapproved injectable tanning products.73
It has no cleared compounding pathway. Melanotan II was in "Category 2" of the FDA's interim 503A bulk-substances list (substances raising significant safety concerns). The FDA removed it - with eleven other peptides - from Category 2 in April 2026, but removal did not place it on the approved list.46
It is not (yet) on the July 2026 agenda. Only seven of the twelve were scheduled for the July 23-24, 2026 advisory meeting; Melanotan II is among the five expected to be taken up in a later review.45
In plain terms, Melanotan II sits in a regulatory gap - out of the explicitly-restricted bucket, but not in any approved one, and still awaiting its own review.
This section is educational and is not legal advice. Rules can vary and change; consult a qualified professional for your situation.
In plain English: It's not approved, the FDA has warned people about it, and it has no legal made-to-order path.
The regulatory timeline
Sep 2023
FDA places this and other peptides in Category 2 of the interim 503A bulks list, citing safety concerns.4
Apr 2026
FDA removes 12 peptides - including this one - from Category 2. Seven are referred to a July 2026 advisory meeting; the remaining five, including this one, are set aside for a later review.46
Later review (reported as early 2027)
The Pharmacy Compounding Advisory Committee is expected to take up the remaining peptides - including this one - at a subsequent meeting. As of July 2026, FDA had not yet posted an official meeting notice or evaluated-use chart for that session.54
After that meeting
Any committee vote is advisory only. The FDA then decides whether to begin formal rulemaking to add (or not add) the peptide to the 503A list - the stage where public comment carries legal weight.7
The "early 2027" timing is reported by legal and industry analysts of the April 2026 action; treat it as anticipated rather than an officially scheduled FDA date until a Federal Register notice confirms it.54
Where the public comes in
Because this peptide is not on the July 2026 agenda, its public docket has not opened yet. When the FDA schedules its review - and, more importantly, if it later opens formal rulemaking - there will be a public comment window. That rulemaking window is the one that carries legal weight, and it is the moment Peppies is tracking.
Want to know the moment you can comment?
Join the list and we'll send a clear, step-by-step heads-up when a comment window opens - for this peptide and the rest. See also our how-to-comment guide.
Is Melanotan II legal in the United States in 2026?
Melanotan II is not FDA-approved and has no cleared compounding pathway. It was removed from Category 2 in April 2026 but is not on the July 2026 agenda; a later review is expected. The FDA has warned consumers against unapproved tanning injections.453
Is Melanotan II dangerous?
Published case reports and reviews document serious adverse events, including rhabdomyolysis, kidney injury, cardiovascular effects, and priapism, and the FDA has warned against unapproved tanning injections. No controlled trial has established a safe dose.123
When will the FDA review Melanotan II?
Not on the July 2026 agenda. A later review is anticipated (reported as early 2027); no official FDA date was confirmed as of July 2026.54
Where to learn more
Want to dig into the primary science yourself? These are neutral, authoritative starting points - no sales pitch, just the record:
We link only to independent, authoritative sources - U.S. and international (NIH, FDA, Europe PMC/EMBL-EBI, and the EU/U.S. trial registries) - never to sellers.
